Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Device-assessed sleep and physical activity in individuals recovering from a hospital admission for COVID-19: a multicentre study.
Plekhanova T, Rowlands AV, Evans RA, Edwardson CL, Bishop NC, Bolton CE, Chalmers JD, Davies MJ, Daynes E, Dempsey PC, Docherty AB, Elneima O, Greening NJ, Greenwood SA, Hall AP, Harris VC, Harrison EM, Henson J, Ho LP, Horsley A, Houchen-Wolloff L, Khunti K, Leavy OC, Lone NI, Marks M, Maylor B, McAuley HJC, Nolan CM, Poinasamy K, Quint JK, Raman B, Richardson M, Sargeant JA, Saunders RM, Sereno M, Shikotra A, Singapuri A, Steiner M, Stensel DJ, Wain LV, Whitney J, Wootton DG, Brightling CE, Man WD, Singh SJ, Yates T; Writing group (on behalf of the PHOSP-COVID Collaborative Group). Plekhanova T, et al. Among authors: chalmers jd. Int J Behav Nutr Phys Act. 2022 Jul 28;19(1):94. doi: 10.1186/s12966-022-01333-w. Int J Behav Nutr Phys Act. 2022. PMID: 35902858 Free PMC article.
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.
Wilkinson T, Dixon R, Page C, Carroll M, Griffiths G, Ho LP, De Soyza A, Felton T, Lewis KE, Phekoo K, Chalmers JD, Gordon A, McGarvey L, Doherty J, Read RC, Shankar-Hari M, Martinez-Alier N, O'Kelly M, Duncan G, Walles R, Sykes J, Summers C, Singh D; ACCORD Collaborators. Wilkinson T, et al. Among authors: chalmers jd. Trials. 2020 Jul 31;21(1):691. doi: 10.1186/s13063-020-04584-9. Trials. 2020. PMID: 32736596 Free PMC article.
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease.
Adeloye D, Elneima O, Daines L, Poinasamy K, Quint JK, Walker S, Brightling CE, Siddiqui S, Hurst JR, Chalmers JD, Pfeffer PE, Novotny P, Drake TM, Heaney LG, Rudan I, Sheikh A, De Soyza A; International COVID-19 Airways Diseases Group. Adeloye D, et al. Among authors: chalmers jd. Lancet Respir Med. 2021 Dec;9(12):1467-1478. doi: 10.1016/S2213-2600(21)00286-1. Epub 2021 Aug 17. Lancet Respir Med. 2021. PMID: 34416191 Free PMC article. Review.
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study.
Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC, Daines L, Baillie JK, Brown JS, Chalder T, De Soyza A, Diar Bakerly N, Easom N, Geddes JR, Greening NJ, Hart N, Heaney LG, Heller S, Howard L, Hurst JR, Jacob J, Jenkins RG, Jolley C, Kerr S, Kon OM, Lewis K, Lord JM, McCann GP, Neubauer S, Openshaw PJM, Parekh D, Pfeffer P, Rahman NM, Raman B, Richardson M, Rowland M, Semple MG, Shah AM, Singh SJ, Sheikh A, Thomas D, Toshner M, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Wain LV, Brightling CE; PHOSP-COVID Collaborative Group. Evans RA, et al. Among authors: chalmers jd. Lancet Respir Med. 2021 Nov;9(11):1275-1287. doi: 10.1016/S2213-2600(21)00383-0. Epub 2021 Oct 7. Lancet Respir Med. 2021. PMID: 34627560 Free PMC article.
COVID-19 follow-up programs across Europe: an ERS END-COVID CRC survey.
Valenzuela C, Nigro M, Chalmers JD, Wagers S, Avinash A, Hellemons ME, Löffler-Ragg J, Brightling CE, Aliberti S. Valenzuela C, et al. Among authors: chalmers jd. Eur Respir J. 2022 Jul 21;60(3):2200923. doi: 10.1183/13993003.00923-2022. Online ahead of print. Eur Respir J. 2022. PMID: 35863767 Free PMC article.
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.
Keir HR, Long MB, Abo-Leyah H, Giam YH, Vadiveloo T, Pembridge T, Hull RC, Delgado L, Band M, McLaren-Neil F, Adamson S, Lahnsteiner E, Gilmour A, Hughes C, New BJ, Connell D, Dowey R, Turton H, Richardson H, Cassidy D, Cooper J, Suntharalingam J, Diwakar L, Russell P, Underwood J, Hicks A, Dosanjh DP, Sage B, Dhasmana D, Spears M, Thompson AR, Brightling C, Smith A, Patel M, George J, Condliffe AM, Shoemark A, MacLennan G, Chalmers JD; STOP-COVID19 Investigators. Keir HR, et al. Among authors: chalmers jd. Lancet Respir Med. 2022 Dec;10(12):1119-1128. doi: 10.1016/S2213-2600(22)00261-2. Epub 2022 Sep 5. Lancet Respir Med. 2022. PMID: 36075243 Free PMC article. Clinical Trial.
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
Wilkinson T, De Soyza A, Carroll M, Chalmers JD, Crooks MG, Griffiths G, Shankar-Hari M, Ho LP, Horsley A, Kell C, Lara B, Mishra B, Moate R, Page C, Pandya H, Raw J, Reid F, Saralaya D, Scott IC, Siddiqui S, Ustianowski A, van Zuydam N, Woodcock A, Singh D. Wilkinson T, et al. Among authors: chalmers jd. ERJ Open Res. 2023 Oct 2;9(5):00249-2023. doi: 10.1183/23120541.00249-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37868151 Free PMC article.
440 results